Shire

ShireShire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

Shire RSS Channel

Display # 
Title Published Date
One family's history of the rare condition Fabry disease through the generations 28 April 2016
Shire to combine with Baxalta, creating the global leader in rare diseases 14 January 2016
Shire partners with CrowdMed to offer US employees an innovative digital crowdsourcing diagnostic service 09 December 2015
Shire acquires Meritage Pharma 24 February 2015
Shire acquires Premacure AB 12 March 2013
Shire and Boston Children's Hospital enter into broad research collaboration 20 November 2012
Shire continued strong product sales performance in Q3 28 October 2011
Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc. 18 May 2011
Shire delivers a strong first quarter performance 28 April 2011
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® 10 January 2011
Shire Expands Pipeline to Treat Orphan Muscle Diseases through Collaboration with Acceleron Pharma 10 September 2010
Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships 01 September 2010
Shire Proposes to Expand Specialist Gastrointestinal Portfolio 04 August 2010
Shire Purchases Strategic Site in Massachusetts 01 July 2010
VYVANSE® - new ADHD treatment option - now available in Canada 02 February 2010
FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity 26 October 2009
Shire Limited has changed its name to Shire plc 01 October 2008
Shire proposes acquisition of Jerini AG for an equity purchase price of €328 million 04 July 2008
Shire plc accelerating new product sales drive revenue growth of 36% 21 February 2008
Shire's ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome 05 October 2007

Most Popular Now

Boehringer Ingelheim increases acce…

Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an eas...

Read more

AstraZeneca licenses Zurampic to Gr…

AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin Ameri...

Read more

Exercise, future anticancer therapy…

Several studies have demonstrated the benefits of exercise to improve the quality of life of people with cancer. But Dr. Fred Saad, urologist-oncologist and researcher at...

Read more

Merck announces survey results expl…

Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks as...

Read more

Pfizer presents promising data from…

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, nex...

Read more

Bayer Science & Education Found…

Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambit...

Read more

Merck Accelerator expands its reach…

Merck, a leading science and technology company, has started this week the application period for the next round of its Accelerator programs in Darmstadt, Germany, and Na...

Read more

Promising treatment prospects for i…

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms...

Read more

Boehringer Ingelheim and Harvard sc…

Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of...

Read more

AstraZeneca enters commercialisatio…

AstraZeneca today announced it has entered into a commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anae...

Read more

New class of protein could treat ca…

A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therap...

Read more

Call for Abstracts: DIA EuroMeeting…

29 - 31 March 2017, Glasgow, UK. The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and acce...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]